<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145482</url>
  </required_header>
  <id_info>
    <org_study_id>2010-05-0007</org_study_id>
    <nct_id>NCT01145482</nct_id>
  </id_info>
  <brief_title>Mechanisms of Insulin Facilitation of Memory</brief_title>
  <official_title>Mechanisms of Insulin Facilitation of Memory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study described in the present application will test the hypothesis that insulin mediated
      facilitation of memory in Alzheimer's disease (AD) is achieved through enhanced glutamatergic
      neurotransmission due to improvements in cerebral glucose metabolism. The effect of a single
      dose of intranasal insulin on memory and cerebral glutamate concentrations in adults with
      mild AD or amnestic mild cognitive impairment (aMCI), the presumed prodromal phase of AD will
      be studied. Successful completion of this study may set the stage for a larger-scale
      treatment trial of intranasal insulin for adults with memory disorders. However, the use of
      insulin in this manner at this point in time is purely experimental.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this project will be accomplished through a cross sectional repeated
      measures design in which 15 participants with mild AD or amnestic MCI will undergo
      assessments of brain structure and function 15 minutes after a single dose of insulin (20 IU)
      or placebo. Insulin and placebo conditions will be counterbalanced across participants.

      Intranasal insulin or placebo administration: Saline and insulin (NovoLog) will be ordered
      though the UT Student Health Services Pharmacy (Sharon Roberson, Chief Pharmacist) and stored
      at 4°C, according to standard pharmacy protocols. Three ml doses of saline or insulin will be
      packaged in nasal spray bottles (e.g., Spectrum Pharmacy Products bottles 969-17404P and
      actuators 551-24362P) designed to deliver 100μL dose with each spray. A total volume of 200μL
      will be delivered during each administration (one 100μL dose in each nostril).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral Glutamate Concentration</measure>
    <time_frame>15 minutes post insulin or placebo administration</time_frame>
    <description>Glutamate concentration was expressed as the ratio of glutamate to creatine. This was determined using magnetic resonance spectroscopy (MRS), a magnetic resonance technique that uses the same equipment as magnetic resonance imaging (MRI), but allows researchers to extract information about the concentrations of various neurochemicals of neurobiological significance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Memory</measure>
    <time_frame>15 minutes post insulin or placebo administration</time_frame>
    <description>Memory performance was assessed using delayed recall (number of units recalled) on the Wechsler Memory Scale (WMS-IV) logical memory (story recall) test. Scores represent a sum of recalled units of two different stories after a 30 minute delay. Total scores range from 0 to 50 (0-25 for each story) with higher scores reflecting better memory performance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Memory Disorders</condition>
  <arm_group>
    <arm_group_label>insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
    <arm_group_label>insulin</arm_group_label>
    <other_name>NovoLog, 20 IU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline, 200 micro liters</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of probable AD

          -  Age over 21

          -  Clinical Dementia Rating of 0.5 or 1.0

          -  Mini Mental State Exam Score&gt;15

        Exclusion Criteria:

          -  preexisting diabetes

          -  significant neurological disease that might affect cognition, other than AD, including
             stroke, Parkinson's disease, multiple sclerosis

          -  severe head injury with loss of consciousness &gt; 30 minutes or with permanent
             neurological sequelae

          -  significant medical illness or organ failure, such as uncontrolled hypertension or
             cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or
             kidney disease

          -  current use of anti-psychotic or anti-convulsant medications

          -  current or previous use of hypoglycemic agents or insulin

          -  MRI contraindications

          -  claustrophobia

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreana P Haley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Austin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <results_first_submitted>April 10, 2014</results_first_submitted>
  <results_first_submitted_qc>October 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2014</results_first_posted>
  <last_update_submitted>October 30, 2014</last_update_submitted>
  <last_update_submitted_qc>October 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Andreana P. Haley</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Memory Disorders</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Insulin First, Then Saline</title>
          <description>20 IU of insulin was administered once daily on two occasions followed by 200 micro liters of saline once daily on two occasions</description>
        </group>
        <group group_id="P2">
          <title>Saline First, Then Insulin</title>
          <description>200 micro liters of saline was administered once daily on two occasions followed by 20 IU of insulin once daily on two occasions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Mean age 74.09, SD = 6.54 Gender, Female = 5, Male = 6</population>
      <group_list>
        <group group_id="B1">
          <title>Insulin First, Then Saline</title>
          <description>20 IU of insulin was administered once daily on two occasions followed by 200 micro liters of saline administered once daily on two occasions</description>
        </group>
        <group group_id="B2">
          <title>Saline First, Then Insulin</title>
          <description>200 micro liters of saline was administered once daily on two occasions followed by 20 IU of insulin administered once daily on two occasions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.8" spread="8.58"/>
                    <measurement group_id="B2" value="74.33" spread="5.92"/>
                    <measurement group_id="B3" value="74.09" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cerebral Glutamate Concentration</title>
        <description>Glutamate concentration was expressed as the ratio of glutamate to creatine. This was determined using magnetic resonance spectroscopy (MRS), a magnetic resonance technique that uses the same equipment as magnetic resonance imaging (MRI), but allows researchers to extract information about the concentrations of various neurochemicals of neurobiological significance.</description>
        <time_frame>15 minutes post insulin or placebo administration</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin</title>
            <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Glutamate Concentration</title>
          <description>Glutamate concentration was expressed as the ratio of glutamate to creatine. This was determined using magnetic resonance spectroscopy (MRS), a magnetic resonance technique that uses the same equipment as magnetic resonance imaging (MRI), but allows researchers to extract information about the concentrations of various neurochemicals of neurobiological significance.</description>
          <population>per protocol</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.12"/>
                    <measurement group_id="O2" value="1.34" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Memory</title>
        <description>Memory performance was assessed using delayed recall (number of units recalled) on the Wechsler Memory Scale (WMS-IV) logical memory (story recall) test. Scores represent a sum of recalled units of two different stories after a 30 minute delay. Total scores range from 0 to 50 (0-25 for each story) with higher scores reflecting better memory performance</description>
        <time_frame>15 minutes post insulin or placebo administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin</title>
            <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Memory</title>
          <description>Memory performance was assessed using delayed recall (number of units recalled) on the Wechsler Memory Scale (WMS-IV) logical memory (story recall) test. Scores represent a sum of recalled units of two different stories after a 30 minute delay. Total scores range from 0 to 50 (0-25 for each story) with higher scores reflecting better memory performance</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" spread="6.25"/>
                    <measurement group_id="O2" value="5.36" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>immediately following study visits</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Insulin</title>
          <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and urge to vomit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andreana Haley</name_or_title>
      <organization>The University of Texas at Austin</organization>
      <phone>512-232-0863</phone>
      <email>haley@psy.utexas.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

